人附睾蛋白4在卵巢癌患者手术前后的变化及其对复发的监测价值
|
摘要
目的分析人附睾蛋白4(HE4)在卵巢癌患者手术前后的水平变化及其对复发的监测价值。方法选取80例卵巢癌患者作为观察组,另选取80例同期体检健康的女性作为对照组,采用酶联免疫吸附法(ELISA)分别对两组的血清进行HE4检测,比较两组HE4水平变化,分析HE4对卵巢癌患者术后复发的监测价值。结果观察组术前及术后1 d、术后1周、术后1个月的HE4水平明显高于对照组,观察组治疗后的HE4水平明显低于治疗前水平(P<0.05);观察组62例患者术前HE4呈阳性,检测灵敏度为81.25%,特异度为33.33%;患者病理分级越低,HE4阳性率越高。结论 HE4对检测卵巢癌具有较高的特异性和敏感性,临床诊断效果显著,值得推广应用,同时HE4还可作为预测卵巢癌患者术后复发的有效评价指标。
Objective Analysis of human epididymis protein 4(HE4) levels in patients with ovarian cancer before and after operation and the influence of which to the recurrence monitoring. Methods 80 cases of ovarian cancer patients were selected as the research object in the experimental group while 80 cases of the same period health examination women were as the control group. By enzyme linked immunosorbent assay(ELISA) serum HE4 of the two groups were detected and compared. The value of analysis the change of the level of the two groups of HE4 for monitoring ovarian cancer recurrence were analyzed. Results The level of HE4 in the experimental group,one day,one weeks and one month after operation was significantly higher than that in the control group. The level of HE4 in the experimental group was significantly lower than that before treatment(P<0.05). experimental group before 62 cases of HE4 in patients were positive,the detection sensitivity was 81.25% and the specificity was 33. 33 %. patients with pathologic stage is low,human epididymis protein 4 was positive rate is high. Conclusions HE4, with high specificity and sensitivity for detection of ovarian cancer,which is significant for the clinical diagnosis effect,is worth promoting the application. Meanwhile,HE4 can be used as an effective evaluation index for predicting the recurrence of ovarian cancer patients.
Objective Analysis of human epididymis protein 4(HE4) levels in patients with ovarian cancer before and after operation and the influence of which to the recurrence monitoring. Methods 80 cases of ovarian cancer patients were selected as the research object in the experimental group while 80 cases of the same period health examination women were as the control group. By enzyme linked immunosorbent assay(ELISA) serum HE4 of the two groups were detected and compared. The value of analysis the change of the level of the two groups of HE4 for monitoring ovarian cancer recurrence were analyzed. Results The level of HE4 in the experimental group,one day,one weeks and one month after operation was significantly higher than that in the control group. The level of HE4 in the experimental group was significantly lower than that before treatment(P<0.05). experimental group before 62 cases of HE4 in patients were positive,the detection sensitivity was 81.25% and the specificity was 33. 33 %. patients with pathologic stage is low,human epididymis protein 4 was positive rate is high. Conclusions HE4, with high specificity and sensitivity for detection of ovarian cancer,which is significant for the clinical diagnosis effect,is worth promoting the application. Meanwhile,HE4 can be used as an effective evaluation index for predicting the recurrence of ovarian cancer patients.
引文
[1]董慧敏,朱远航,宋志兴,等.血清HE4、VEGF和CRP的联合检测在预测卵巢癌术后早期复发中的价值[J].中国卫生检验杂志,2014,24(11):1590-1592.
[2]黄思毅,曾钦凤.HE4 CA125和sB7-H4联合检测在卵巢癌早期诊断的临床价值[J].河北医学,2011,17(4):443-445.
[3]宋晓翠,张文珺,滕洪涛,等.血清HE4、CA125联合检测在卵巢癌术后复发诊断中的应用[J].山东医药,2012,52(14):75-76.
[4]陈戴娣,陈寒凌,刘彩芬.监测上皮性卵巢癌患者术后血清HE4和CA125水平的价值[J].国际妇产科学杂志,2015,42(5):594-596.
[5]吴少芳,刘艳红.人附睾蛋白4在卵巢上皮癌诊断中的应用价值[J].中华全科医学,2013,11(7):1111-1112.
[6]刘倩,郭健.HE4和CA125监测老年卵巢癌转归的价值[J].标记免疫分析与临床,2011,18(6):374-379.
[7]贾素娟,王治洁,张美琴,等.血清CA125、HE4和影像学检查在上皮性卵巢癌术后复发诊断中的应用价值[J].中国癌症杂志,2015,25(6):451-455.
[8]黄静.血清CA125、HE4和YKL-40联合检测对卵巢恶性肿瘤的诊断价值[J].中国医刊,2014,49(2):69-70.
[9]董慧敏,朱远航,宋志兴,等.血清HE4、VEGF和CRP的联合检测在预测卵巢癌术后早期复发中的价值[J].中国卫生检验杂志,2014,24(11):1590-1592.
[10]惠慧,吴磊,杨新园.HE4检测对卵巢癌手术结果的预测分析[J].西部医学,2015,27(5):751-752,755.
[11]苏彤,刘辉,任清霞,等.HE4、TSGF和CA125联合检测诊断卵巢癌的价值[J].山东医药,2011,51(39):62-64.
[12]周善良.血清HE4,CA125与TSGF联合检测在卵巢恶性肿瘤诊断中的价值[J].现代中西医结合杂志,2012,21(31):3500-3501.
[13]范群,李玉芳,范姜铱柔,等.血清HE4、TSGF和CA125联合检测诊断卵巢癌的价值[J].海南医学,2015,37(11):1634-1636.
[14]王芝琴,许剑,陈茵,等.卵巢癌患者血清和肿瘤组织HE4和CA125联合检测的临床意义[J].实用癌症杂志,2014,21(4):412-414.
[15]朱自力,戴伟萍,肖春红,等.血清HE4,CA125联合ROMA指数在卵巢癌预测和诊断中的应用价值[J].现代检验医学杂志,2014,29(2):76-77.
[16]尚陈宇,刘冬冬,徐建华,等.HE4和CA125联合检测在卵巢癌诊断及预后评估中的价值研究[J].中国妇幼保健,2014,29(33):5492-5494.
[17]程洪艳,刘亚南,叶雪,等.血清人附睾分泌蛋白4(HE4)和CA(125)在卵巢癌患者手术及化疗前后的变化[J].中国妇产科临床杂志,2011,12(3):212-215.
[2]黄思毅,曾钦凤.HE4 CA125和sB7-H4联合检测在卵巢癌早期诊断的临床价值[J].河北医学,2011,17(4):443-445.
[3]宋晓翠,张文珺,滕洪涛,等.血清HE4、CA125联合检测在卵巢癌术后复发诊断中的应用[J].山东医药,2012,52(14):75-76.
[4]陈戴娣,陈寒凌,刘彩芬.监测上皮性卵巢癌患者术后血清HE4和CA125水平的价值[J].国际妇产科学杂志,2015,42(5):594-596.
[5]吴少芳,刘艳红.人附睾蛋白4在卵巢上皮癌诊断中的应用价值[J].中华全科医学,2013,11(7):1111-1112.
[6]刘倩,郭健.HE4和CA125监测老年卵巢癌转归的价值[J].标记免疫分析与临床,2011,18(6):374-379.
[7]贾素娟,王治洁,张美琴,等.血清CA125、HE4和影像学检查在上皮性卵巢癌术后复发诊断中的应用价值[J].中国癌症杂志,2015,25(6):451-455.
[8]黄静.血清CA125、HE4和YKL-40联合检测对卵巢恶性肿瘤的诊断价值[J].中国医刊,2014,49(2):69-70.
[9]董慧敏,朱远航,宋志兴,等.血清HE4、VEGF和CRP的联合检测在预测卵巢癌术后早期复发中的价值[J].中国卫生检验杂志,2014,24(11):1590-1592.
[10]惠慧,吴磊,杨新园.HE4检测对卵巢癌手术结果的预测分析[J].西部医学,2015,27(5):751-752,755.
[11]苏彤,刘辉,任清霞,等.HE4、TSGF和CA125联合检测诊断卵巢癌的价值[J].山东医药,2011,51(39):62-64.
[12]周善良.血清HE4,CA125与TSGF联合检测在卵巢恶性肿瘤诊断中的价值[J].现代中西医结合杂志,2012,21(31):3500-3501.
[13]范群,李玉芳,范姜铱柔,等.血清HE4、TSGF和CA125联合检测诊断卵巢癌的价值[J].海南医学,2015,37(11):1634-1636.
[14]王芝琴,许剑,陈茵,等.卵巢癌患者血清和肿瘤组织HE4和CA125联合检测的临床意义[J].实用癌症杂志,2014,21(4):412-414.
[15]朱自力,戴伟萍,肖春红,等.血清HE4,CA125联合ROMA指数在卵巢癌预测和诊断中的应用价值[J].现代检验医学杂志,2014,29(2):76-77.
[16]尚陈宇,刘冬冬,徐建华,等.HE4和CA125联合检测在卵巢癌诊断及预后评估中的价值研究[J].中国妇幼保健,2014,29(33):5492-5494.
[17]程洪艳,刘亚南,叶雪,等.血清人附睾分泌蛋白4(HE4)和CA(125)在卵巢癌患者手术及化疗前后的变化[J].中国妇产科临床杂志,2011,12(3):212-215.